<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of a 37-year-old pregnant patient with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS), who has a medical history of both <z:mp ids='MP_0005048'>thrombosis</z:mp> and recurrent fetal loss, is presented </plain></SENT>
<SENT sid="1" pm="."><plain>She was treated with predonisolone and fixed-dose unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> (UFH) infusion, followed by plasmaphereses and fixed-dose low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> infusion during her fourth pregnancy </plain></SENT>
<SENT sid="2" pm="."><plain>Unfortunately, this treatment did not have beneficial effects, resulting in <z:hpo ids='HP_0001511'>intrauterine growth restriction</z:hpo> and finally <z:hpo ids='HP_0003811'>neonatal death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Continuous intravenous UFH infusion and low-dose aspirin were administrated under the monitoring of the activated partial thromboplastin time to achieve a target level of 120 s during her fifth pregnancy </plain></SENT>
<SENT sid="4" pm="."><plain>A healthy baby weighing 1818 g at birth was delivered by Cesarean section at the 34th week of pregnancy </plain></SENT>
<SENT sid="5" pm="."><plain>High-dose UFH infusion may be considered to be one of the preferable options to manage pregnant patients with refractory APS </plain></SENT>
</text></document>